Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Santarus Inc. Shares Charged Higher

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Santarus Inc.  (UNKNOWN: SNTS.DL  ) , a specialty biopharmaceutical company, jumped as much as 13% after handily trouncing Wall Street's estimates in the second-quarter and boosting its full-year outlook.

So what: For the quarter, Santarus reported a huge gain in revenue of 89% to $89.4 million and a blistering adjusted profit of $0.31 per share compared to just $0.10 in EPS in the year-ago period. Furthermore, this doesn't include a nearly $55 million one-time tax benefit that Santarus recognized during the quarter. Newly approved Uceris -- designed to treat mild to moderate ulcerative colitis -- recognized $16 million in revenue, more than double what it reported in the sequential quarter, while upper gastrointestinal disorder drug Zegerid saw sales jump 110% to $21.6 million. For the quarter, Wall Street had been expecting just $0.16 in EPS on $82.9 million in revenue. Looking ahead, Santarus also boosted its full-year guidance to a range of $355 million to $360 million in revenue and EPS of $1.21-$1.26 from its prior outlook that called for $330 million to $340 million in sales and $1.03-$1.15 in EPS.

Now what: I keep thinking the run in Santarus is over, and it just keeps plugging forward. Thus far, the launch of Uceris has gone as planned, but the big surprise has been just how quickly sales of Zegerid have rebounded and how strong sales have been for its largest revenue-generating product, Glumetza. However, I still have a hard time wrapping my hands around Santarus at 20 times forward earnings with the stock having already quintupled in a year's time span. I can't help but think much of its future growth is already well-baked into its share price here.

It's no secret that biotech stocks like Santarus have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2584081, ~/Articles/ArticleHandler.aspx, 9/27/2016 8:07:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
SNTS.DL $0.00 Down +0.00 +0.00%
Santarus CAPS Rating: *****